Targeting low-density lipoprotein receptor (LDLR) with LXR agonist causes inducible degrader of LDLR (IDOL)-mediated LDLR degradation and increased expression of the cholesterol efflux transporter to promote tumor cell death in glioblastoma [92]. Here, LDLR is linked to neoplasm.